AAPL   366.37 (+0.62%)
MSFT   207.45 (+1.34%)
FB   234.07 (-1.47%)
NVDA   386.99 (+1.52%)
MU   50.22 (+1.05%)
GE   6.82 (+1.19%)
TSLA   1,209.24 (+8.00%)
T   30.30 (+1.30%)
GILD   76.69 (+0.82%)
DIS   112.89 (-0.12%)
AAPL   366.37 (+0.62%)
MSFT   207.45 (+1.34%)
FB   234.07 (-1.47%)
NVDA   386.99 (+1.52%)
MU   50.22 (+1.05%)
GE   6.82 (+1.19%)
TSLA   1,209.24 (+8.00%)
T   30.30 (+1.30%)
GILD   76.69 (+0.82%)
DIS   112.89 (-0.12%)
AAPL   366.37 (+0.62%)
MSFT   207.45 (+1.34%)
FB   234.07 (-1.47%)
NVDA   386.99 (+1.52%)
MU   50.22 (+1.05%)
GE   6.82 (+1.19%)
TSLA   1,209.24 (+8.00%)
T   30.30 (+1.30%)
GILD   76.69 (+0.82%)
DIS   112.89 (-0.12%)
AAPL   366.37 (+0.62%)
MSFT   207.45 (+1.34%)
FB   234.07 (-1.47%)
NVDA   386.99 (+1.52%)
MU   50.22 (+1.05%)
GE   6.82 (+1.19%)
TSLA   1,209.24 (+8.00%)
T   30.30 (+1.30%)
GILD   76.69 (+0.82%)
DIS   112.89 (-0.12%)
Log in

NASDAQ:RKDAArcadia Biosciences Earnings Date, Estimates & History

$3.77
-0.17 (-4.31 %)
(As of 07/2/2020 03:28 PM ET)
Add
Compare
Today's Range
$3.75
Now: $3.77▼
$3.96
50-Day Range
$3.58
MA: $3.96▼
$4.82
52-Week Range
$1.82
Now: $3.77▼
$10.20
Volume5,733 shs
Average Volume329,008 shs
Market Capitalization$32.61 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.81

Earnings

Arcadia Biosciences (NASDAQ:RKDA) Earnings Information

Arcadia Biosciences last posted its earnings data on May 13th, 2020. The basic materials company reported $0.29 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.84. The company had revenue of $0.31 million for the quarter, compared to analyst estimates of $0.60 million. Arcadia Biosciences has generated ($3.37) earnings per share over the last year. Arcadia Biosciences has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 12th, 2020 based off prior year's report dates.

Arcadia Biosciences Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Arcadia Biosciences (NASDAQ:RKDA) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20201($0.70)($0.70)($0.70)
Q3 20201($0.57)($0.57)($0.57)
Q4 20201($0.46)($0.46)($0.46)

Arcadia Biosciences (NASDAQ RKDA) Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSGAAP EPSRevenue EstimateActual RevenueConference CallDetails
8/12/2020
(Estimated)		       
5/13/20203/31/2020($0.55)$0.29($1.19)$0.60 million$0.31 millionTranscript
3/25/202012/31/2019($0.61)($0.50)($0.26)$0.40 million$0.42 millionTranscript
11/6/2019Q3($0.77)($2.04)$0.20$0.31 million$0.39 millionTranscript
8/14/2019Q2 2019($0.88)($0.96)($2.76)$0.20 million$0.20 millionN/A
5/8/20193/31/2019($0.61)($1.24)$0.16$0.40 million$0.16 millionN/A
3/27/201912/31/2018($0.76)($0.14)($0.14)$0.30 million$0.44 millionTranscript
11/7/20189/30/2018($1.13)$0.93($1.85)$0.26 million$0.37 millionTranscript
8/10/2018Q2 2018($1.29)($2.0160)($2.02)$0.20 million$0.44 millionN/A
5/9/2018Q1 2018($4.86)($4.86)$0.21 millionN/A
3/20/2018Q4 2017($2.00)($1.39)($1.39)$1.43 millionN/A
11/9/2017Q3 2017($1.60)($2.20)($0.11)$0.59 millionN/A
8/10/2017Q2 2017($2.20)($1.88)($0.09)$0.99 millionN/A
5/10/2017Q1 2017($1.40)($2.00)($0.10)$1.02 millionN/A
3/8/2017Q4 2016($2.00)($2.60)($2.60)$0.54 millionListen
11/10/2016Q3 2016($1.40)($1.80)($1.80)$2.10 million$1.08 millionListen
8/9/2016Q2 2016($1.40)($2.00)($2.00)$1.90 million$0.72 millionListen
5/10/2016Q1 2016($1.40)($2.40)($2.40)$1.60 million$0.85 millionListen
3/8/2016Q4 2015($1.40)($1.60)($1.40)$2.40 million$1.35 millionListen
11/5/2015Q3 2015($1.40)($2.20)($2.20)$2.40 million$1.82 millionN/A
8/10/2015Q2 2015($3.80)($3.80)$2.90 million$1.43 millionListen
(Earnings results data provided by Zacks Investment Research)
This page was last updated on 7/2/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.